In:
International Journal of Cancer, Wiley, Vol. 145, No. 9 ( 2019-11), p. 2547-2557
Abstract:
What's new? Liquid biopsy is increasingly being integrated into cancer diagnostics and surveillance. However, critical questions still remain, such as how to precisely evaluate cancer mutation burden and infer clinical implications. Here, the authors develop a new algorithm that evaluates in an unbiased manner the mutation deviation of every single site in the target regions covered by a cancer panel, including the sites that usually fail to pass the single nucleotide variations (SNV)‐calling criteria of most algorithms. By analyzing 93 cervical cancer samples, they demonstrate that this algorithm is able to efficiently monitor patient response to treatment and prognosticate tumor progression.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
